Cantor Fitzgerald Maintains Overweight on NewAmsterdam Pharma Co, Raises Price Target to $61
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Cantor Fitzgerald analyst Steve Seedhouse maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Overweight and raises the price target from $52 to $61.
Cantor Fitzgerald analyst Steve Seedhouse maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Overweight and raises the price target from $52 to $61.